Management of autosomal-dominant polycystic kidney disease—state-of-the-art
Open Access
- 1 December 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 11 (suppl_1) , i2-i13
Abstract
Autosomal-dominant polycystic kidney disease (ADPKD) is the most frequent genetic cause of end-stage renal disease in adults. Affected individuals and families face a significant medical and psychosocial burden due to both renal and extrarenal manifestations. Consequently, interventions that ameliorate the course of the disease and specifically slow down the loss of kidney function are of special interest. Major research efforts in both the clinical and pre-clinical setting in the last two decades resulted in a number of pivotal clinical trials aimed to ameliorate the disease. These studies have underlined the important role of specific supportive measures and provided the basis for first targeted pharmacological therapies. Very recently, the concept of repurposing drugs approved for other conditions for a use in ADPKD has gained increasing attention. Here, we review the current best-practice management of ADPKD patients with a focus on interventions that have reached clinical use to maintain kidney function and give an outlook on future trials and potential novel treatment strategies.Keywords
Funding Information
- Ministry of Culture and Science Northrine-Westfalia
This publication has 122 references indexed in Scilit:
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Leisure Time Physical Activity of Moderate to Vigorous Intensity and Mortality: A Large Pooled Cohort AnalysisPLOS Medicine, 2012
- Activating AMP-activated protein kinase (AMPK) slows renal cystogenesisProceedings of the National Academy of Sciences of the United States of America, 2011
- Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse modelsNature Medicine, 2010
- Rapamycin Ameliorates PKD Resulting from Conditional Inactivation of Pkd1Journal of the American Society of Nephrology, 2010
- Projected Effect of Dietary Salt Reductions on Future Cardiovascular DiseaseNew England Journal of Medicine, 2010
- Physical Activity and Mortality in Chronic Kidney Disease (NHANES III)Clinical Journal of the American Society of Nephrology, 2009
- Autosomal dominant polycystic kidney disease: the last 3 yearsKidney International, 2009
- Thiophenecarboxylate Suppressor of Cyclic Nucleotides Discovered in a Small-Molecule Screen Blocks Toxin-Induced Intestinal Fluid SecretionMolecular Pharmacology, 2009
- Vasopressin Directly Regulates Cyst Growth in Polycystic Kidney DiseaseJournal of the American Society of Nephrology, 2008